The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities
Open accessAbstract
Human tissues express cannabinoid CB 1 and CB 2 receptors that can be activated by endogenously released ‘endocannabinoids’ or exogenously administered compounds in a manner that reduces the symptoms or opposes the underlying causes of several disorders in need of effective therapy. Three medicines that activate cannabinoid CB 1 /CB 2 receptors are now in the clinic: Cesamet (nabilone), Marinol (dronabinol; Δ 9 -tetrahydrocannabinol ( Δ 9 -THC)) and Sativex ( Δ 9 -THC with cannabidiol). These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (Cesamet and Marinol), stimulation of appetite (Marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (Sativex). This review mentions several possible additional therapeutic targets for cannabinoid receptor agonists. These include other kinds of pain, epilepsy, anxiety, depression, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders. It also describes potential strategies for improving the efficacy and/or benefit-to-risk ratio of these agonists in the clinic. These are strategies that involve (i) targeting cannabinoid receptors located outside the blood-brain barrier, (ii) targeting cannabinoid receptors expressed by a particular tissue, (iii) targeting upregulated cannabinoid receptors, (iv) selectively targeting cannabinoid CB 2 receptors, and/or (v) adjunctive ‘multi-targeting’.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Self-citationCannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Self-citationCannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
Steffens, S., Veillard, N. R., Arnaud, C., Pelli, G., Burger, F., Staub, C., Zimmer, A., Frossard, J.-L., & Mach, F. (2005) · Nature · doi:10.1038/nature03389 · Cited by 472
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
Self-citationGuindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397
Behavioural and biochemical evidence for interactions between Δ9‐tetrahydrocannabinol and nicotine
Valjent, E., Mitchell, J. M., Besson, M., Caboche, J., & Maldonado, R. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704479 · Cited by 321
Cannabinoid–Opioid Interaction in Chronic Pain
Abrams, D. I., Couey, P., Shade, S. B., Kelly, M. E., & Benowitz, N. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.188 · Cited by 319
Synergistic interactions between cannabinoid and opioid analgesics
Cichewicz, D. L. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.038 · Cited by 305
A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., García-Taboada, E., Barcia, J., Guzmán, M., & Velasco, G. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0688 · Cited by 301
Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence
Le Foll, B., & Goldberg, S. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077974 · Cited by 291
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S., & Reggiani, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04684.x · Cited by 290
Ellgren, M., Spano, S. M., & Hurd, Y. L. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301127 · Cited by 287
Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
Vara, D., Salazar, M., Olea-Herrero, N., Guzmán, M., Velasco, G., & Díaz-Laviada, I. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.32 · Cited by 268
Wright, K. L., Duncan, M., & Sharkey, K. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707486 · Cited by 264
Louvet, A., Teixeira-Clerc, F., Chobert, M.-N., Deveaux, V., Pavoine, C., Zimmer, A., Pecker, F., Mallat, A., & Lotersztajn, S. (2011) · Hepatology · doi:10.1002/hep.24524 · Cited by 261
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy
Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., & Jamison, R. N. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.10.018 · Cited by 257
Ramirez, S. H., Haskó, J., Skuba, A., Fan, S., Dykstra, H., McCormick, R., Reichenbach, N., Krizbai, I., Mahadevan, A., Zhang, M., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4628-11.2012 · Cited by 237
Donadelli, M., Dando, I., Zaniboni, T., Costanzo, C., Dalla Pozza, E., Scupoli, M. T., Scarpa, A., Zappavigna, S., Marra, M., Abbruzzese, A., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.36 · Cited by 228
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
Pacher, P., & Haskó, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707582 · Cited by 217
García, C., Palomo‐Garo, C., García‐Arencibia, M., Ramos, J., Pertwee, R., & Fernández‐Ruiz, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01278.x · Cited by 211
Self-citationNaef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A., & Brenneisen, R. (2003) · Pain · doi:10.1016/s0304-3959(03)00163-5 · Cited by 209
Shoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P., & Prather, P. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04346.x · Cited by 207
Pertwee, R. G. (2005) · The AAPS Journal · doi:10.1208/aapsj070364 · Cited by 203
Self-citationThe endocannabinoid system and cancer: therapeutic implication
Guindon, J., & Hohmann, A. G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01327.x · Cited by 200
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects
Izzo, A. A., & Camilleri, M. (2008) · Gut · doi:10.1136/gut.2008.148791 · Cited by 199
Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease
Basu, S., & Dittel, B. N. (2011) · Immunologic Research · doi:10.1007/s12026-011-8210-5 · Cited by 192
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Petrosino, S., & Marzo, V. D. (2010) · PubMed · Cited by 184
The future of endocannabinoid-oriented clinical research after CB1 antagonists
Le Foll, B., Gorelick, D. A., & Goldberg, S. R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1506-7 · Cited by 167
Zhang, M., Martin, B. R., Adler, M. W., Razdan, R. K., Jallo, J. I., & Tuma, R. F. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600447 · Cited by 164
Anavi‐Goffer, S., Baillie, G. L., Irving, A. J., Gertsch, J., Greig, I. R., Pertwee, R. G., & Ross, R. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296020 · Cited by 159
Self-citationHistamine induced responses are attenuated by a cannabinoid receptor agonist in human skin
Dvorak, M., Watkinson, A., McGlone, F. P., & Rukwied, R. (2003) · Inflammation Research · doi:10.1007/s00011-003-1162-z · Cited by 157
Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration
Cichewicz, D. L., & McCarthy, E. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045575 · Cited by 154
Kim, K., Moore, D. H., Makriyannis, A., & Abood, M. E. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.05.025 · Cited by 153
Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy
Barutta, F., Piscitelli, F., Pinach, S., Bruno, G., Gambino, R., Rastaldi, M. P., Salvidio, G., Marzo, V. D., Perin, P. C., & Gruden, G. (2011) · Diabetes · doi:10.2337/db10-1809 · Cited by 145
Pryce, G., & Baker, D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707003 · Cited by 144
Cannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 142
Self-citationBolognini, D., Costa, B., Maione, S., Comelli, F., Marini, P., Marzo, V. D., Parolaro, D., Ross, R. A., Gauson, L. A., Cascio, M. G., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00756.x · Cited by 140
Self-citationMallat, A., Teixeira-Clerc, F., Deveaux, V., Manin, S., & Lotersztajn, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01397.x · Cited by 137
Pain relief with oral cannabinoids in familial Mediterranean fever
Holdcroft, A., Smith, M., Jacklin, A., Hodgson, H. J. F., Smith, B., Newton, M., & Evans, F. J. (1997) · Anaesthesia · doi:10.1111/j.1365-2044.1997.139-az0132.x · Cited by 137
Prospects for cannabinoid therapies in basal ganglia disorders
Fernández‐Ruíz, J., Moreno‐Martet, M., Rodríguez‐Cueto, C., Palomo‐Garo, C., Gómez‐Cañas, M., Valdeolivas, S., Guaza, C., Romero, J., Guzmán, M., Mechoulam, R., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01365.x · Cited by 136
Kwiatkowska, M., Parker, L., Burton, P., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1739-9 · Cited by 135
Whiteside, G. T., Lee, G. P., & Valenzano, K. J. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780363023 · Cited by 135
Romero-Sandoval, A. E., & Eisenach, J. C. (2007) · Anesthesiology · doi:10.1097/01.anes.0000264765.33673.6c · Cited by 134
Singh, U. P., Singh, N. P., Singh, B., Price, R. L., Nagarkatti, M., & Nagarkatti, P. S. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.11.005 · Cited by 129
Braida, D., Limonta, V., Malabarba, L., Zani, A., & Sala, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.10.038 · Cited by 128
Activation of endocannabinoid transmission induces antidepressant-like effects in rats.
Adamczyk, P., Gołda, A., McCreary, A. C., Filip, M., & Przegaliński, E. (2008) · PubMed · Cited by 123
Zhang, M., Martin, B. R., Adler, M. W., Razdan, R. K., Ganea, D., & Tuma, R. F. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.01.022 · Cited by 116
CB2 receptors as new therapeutic targets for liver diseases
Lotersztajn, S., Teixeira-Clerc, F., Julien, B., Deveaux, V., Ichigotani, Y., Manin, S., Nhieu, J. T. V., Karsak, M., Zimmer, A., & Mallat, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707511 · Cited by 114
Persidsky, Y., Ho, W., Ramirez, S. H., Potula, R., Abood, M. E., Unterwald, E. M., & Tuma, R. F. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.03.001 · Cited by 109
Cannabinoid agonists attenuate capsaicin-induced responses in human skin
Rukwied, R., Watkinson, A., McGlone, F. P., & Dvorak, M. M. (2003) · Pain · doi:10.1016/s0304-3959(02)00401-3 · Cited by 108
Guindon, J., Léan, A. D., & Beaulieu, P. (2006) · Pain · doi:10.1016/j.pain.2005.12.007 · Cited by 107
Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice
Balerio, G. N., Aso, E., & Maldonado, R. J. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0251-9 · Cited by 105
Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine
Roberts, J. D., Gennings, C., & Shih, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.036 · Cited by 103
Yu, X. H., Cao, C. Q., Martino, G., Puma, C., Morinville, A., St-Onge, S., Lessard, É., Perkins, M., & Laird, J. M. A. (2010) · Pain · doi:10.1016/j.pain.2010.07.019 · Cited by 103
Cannabinoids and the skeleton: From marijuana to reversal of bone loss
Bab, I., Zimmer, A. D., & Melamed, E. (2009) · Annals of Medicine · doi:10.1080/07853890903121025 · Cited by 103
Wilkerson, J. L., Gentry, K. R., Dengler, E. C., Wallace, J. A., Kerwin, A. A., Armijo, L. M., Kuhn, M. N., Thakur, G. A., Makriyannis, A., & Milligan, E. D. (2012) · Pain · doi:10.1016/j.pain.2012.02.015 · Cited by 101
Nasser, M. W., Qamri, Z., Deol, Y. S., Smith, D. L., Shilo, K., Zou, X., & Ganju, R. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023901 · Cited by 99
Tham, S. M., Angus, J. A., Tudor, E. M., & Wright, C. E. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706045 · Cited by 98
Dziadulewicz, E. K., Bevan, S., Brain, C. T., Coote, P. R., Culshaw, A. J., Aj, D., Edwards, L. J., Fisher, A. J., Fox, A. J., Gentry, C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070317a · Cited by 96
Topical cannabinoid enhances topical morphine antinociception
Yeşilyurt, Ö., Dogrul, A., Gül, H., Seyrek, M., Kusmez, O., Özkan, Y., & Yıldız, O. (2003) · Pain · doi:10.1016/s0304-3959(03)00245-8 · Cited by 95
Interaction of the cannabinoid and opioid systems in the modulation of nociception
Welch, S. P. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782794 · Cited by 94
Yamamoto, W., Mikami, T., & Iwamura, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.010 · Cited by 89
Kinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.022 · Cited by 89
Reche, I., Fuentes, J. A., & Ruiz-Gayo, M. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00752-2 · Cited by 87
Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice
Naderi, N., Haghparast, A., Saber-Tehrani, A. S., Rezaii, N., Alizadeh, A.-M., Khani, A., & Motamedi, F. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.11.001 · Cited by 87
Marquart, S., Zerr, P., Akhmetshina, A., Palumbo, K., Reich, N., Tomčík, M., Horn, A., Dees, C., Engel, M., Zwerina, J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27642 · Cited by 85
Smith, P. A., Selley, D. E., Sim-Selley, L. J., & Welch, S. P. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.001 · Cited by 81
Elliott, M. B., Tuma, R. F., Amenta, P. S., Barbe, M. F., & Jallo, J. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1672 · Cited by 81
Cannabinoid CB2 receptor‐mediated regulation of impulsive‐like behaviour in DBA/2 mice
Navarrete, F., Pérez‐Ortiz, J. M., & Manzanares, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01542.x · Cited by 80
Modulation of Inflammatory Responses by a Cannabinoid-2–Selective Agonist after Spinal Cord Injury
Adhikary, S., Li, H., Heller, J. E., Škarica, M., Zhang, M., Ganea, D., & Tuma, R. F. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2011.1853 · Cited by 79
Update on the endocannabinoid system as an anticancer target
Malfitano, A. M., Ciaglia, E., Gangemi, G., Gazzerro, P., Laezza, C., & Bifulco, M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.553606 · Cited by 79
Synergy between Δ9-tetrahydrocannabinol and morphine in the arthritic rat
Cox, M. L., Haller, V. L., & Welch, S. P. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.04.010 · Cited by 78
Finn, D. P., Beckett, S. R. G., Roe, C. H., Madjd, A., Fone, K. C. F., Kendall, D. A., Marsden, C. A., & Chapman, V. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03177.x · Cited by 77
Khasabova, I. A., Chandiramani, A., Harding-Rose, C., Simone, D. A., & Seybold, V. S. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.03.007 · Cited by 77
Topical cannabinoid antinociception: synergy with spinal sites
Dogrul, A., Gül, H., Akar, A., Yıldız, O., Bilgin, F., & Güzeldemir, M. E. (2003) · Pain · doi:10.1016/s0304-3959(03)00068-x · Cited by 76
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain
Gutierrez, T., Crystal, J. D., Zvonok, A. M., Makriyannis, A., & Hohmann, A. G. (2011) · Pain · doi:10.1016/j.pain.2011.03.038 · Cited by 73
Cannabinoid agonist-induced sensitisation to morphine place preference in mice
Manzanedo, C., Aguilar, M. A., Rodríguez‐Arias, M., Navarro, M. A., & Miñarro, J. (2004) · Neuroreport · doi:10.1097/01.wnr.0000126217.87116.8c · Cited by 71
The Additive Antinociceptive Interaction Between WIN 55,212-2, a Cannabinoid Agonist, and Ketorolac
Ulugöl, A., Özyiğit, F., Yeşilyurt, Ö., & Dogrul, A. B. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000194587.94260.1d · Cited by 66
Gamaleddin, I., Zvonok, A. M., Makriyannis, A., Goldberg, S. R., & Foll, B. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029900 · Cited by 65
Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo
Hoyer, F. F., Steinmetz, M., Zimmer, S., Becker, A., Lütjohann, D., Buchalla, R., Zimmer, A., & Nickenig, G. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.08.008 · Cited by 62
Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases
Mallat, A., Teixeira-Clerc, F., Deveaux, V., & Lotersztajn, S. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.403 · Cited by 62
Paszcuk, A. F., Dutra, R. C., Silva, K. A. B. S., Quintão, N. L. M., Campos, M. M., & Calixto, J. Β. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024034 · Cited by 58
Li, J., McMahon, L. R., Gerak, L. R., Becker, G. L., & France, C. P. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1157-0 · Cited by 57
Rahn, E. J., Thakur, G. A., Wood, J. A. T., Zvonok, A. M., Makriyannis, A., & Hohmann, A. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.024 · Cited by 57
Yoon, M. H., & Choi, J. I. (2003) · Anesthesiology · doi:10.1097/00000542-200309000-00027 · Cited by 57
Gu, X., Mei, F.-M., Liu, Y., Zhang, R., Zhang, J., & Ma, Z. (2011) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31821d1062 · Cited by 57
Discovery of S-777469: An orally available CB2 agonist as an antipruritic agent
Odan, M., Ishizuka, N., Hiramatsu, Y., Inagaki, M., Hashizume, H., Fujii, Y., Mitsumori, S., Morioka, Y., Soga, M., Deguchi, M., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.072 · Cited by 56
CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain
Khasabova, I. A., Gielissen, J. M., Chandiramani, A., Harding-Rose, C., Odeh, D. A., Simone, D. A., & Seybold, V. S. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283474a6d · Cited by 55
Naderi, N., Ahari, F. A., Shafaghi, B., Najarkolaei, A. H., & Motamedi, F. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0076-x · Cited by 55
Ahn, D. K., Choi, H. S., Yeo, S. P., Woo, Y. W., Lee, M. K., Yang, G. Y., Jeon, H., Park, J. S., & Mokha, S. S. (2007) · Pain · doi:10.1016/j.pain.2007.01.015 · Cited by 52
Potenzieri, C., Harding-Rose, C., & Simone, D. A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.063 · Cited by 52
G-protein coupled receptors regulating cough
Maher, S. A., Dubuis, E. D., & Belvisi, M. G. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.06.005 · Cited by 50
Bátkai, S., Mukhopadhyay, P., Horváth, B., Rajesh, M., Gao, R. Y., Mahadevan, A., Mukkanti, A., Battista, N., Lichtman, A. H., Gauson, L. A., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01410.x · Cited by 48
Self-citationTumati, S., Largent‐Milnes, T. M., Keresztes, A. I., Ren, J., Roeske, W. R., Vanderah, T. W., & Varga, E. V. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.12.021 · Cited by 45
Bahremand, A., Shafaroodi, H., Ghasemi, M., Nasrabady, S. E., Gholizadeh, S., & Dehpour, A. R. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.04.010 · Cited by 43
Seeling, W., Kneer, L., Büchele, B., Gschwend, J. E., Maier, L., Nett, C., Simmet, T., Steffen, P., Schneider, M., & Rockemann, M. (2006) · Der Anaesthesist · doi:10.1007/s00101-005-0963-6 · Cited by 42
van der Stelt, M., Cals, J., Broeders-Josten, S., Cottney, J. E., van der Doelen, A. A., Hermkens, M., de Kimpe, V., King, A. W. T., Klomp, J. P. G., Oosterom, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200916p · Cited by 40
Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family
Bab, I., Smoum, R., Bradshaw, H. B., & Mechoulam, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01474.x · Cited by 39
Gholizadeh, S., Shafaroodi, H., Ghasemi, M., Bahremand, A., Sharifzadeh, M. S., & Dehpour, A. R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.005 · Cited by 38
Łuszczki, J. J., Andres‐Mach, M., Barcicka-Kłosowska, B., Florek-Łuszczki, M., Haratym-Maj, A., & Czuczwar, S. J. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.07.001 · Cited by 38
Hama, A. T., & Sagen, J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.004 · Cited by 36
Magina, S., Kozmus, C. P., Moura, E., Serrão, P., Moura, D., Petrosino, S., Marzo, V. D., & Vieira‐Coelho, M. A. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1126-z · Cited by 35
Marchese, G., Casti, P., Ruiu, S., Saba, P., Sanna, A., Casu, G., & Pani, L. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705478 · Cited by 34
Cui, J. H., Kim, W. M., Lee, H. G., Kim, Y. O., Kim, C. M., & Yoon, M. H. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2010.12.052 · Cited by 33
Cichewicz, D. L., Welch, S. P., & Smith, F. L. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.09.039 · Cited by 33
Łuszczki, J. J., Czuczwar, P., Cioczek‐Czuczwar, A., Dudra-Jastrzębska, M., Andres‐Mach, M., & Czuczwar, S. J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.09.005 · Cited by 32
5-Sulfonyl-benzimidazoles as selective CB2 agonists-Part 2
Gijsen, H. J. M., Cleyn, M. A. J. D., Surkyn, M., Lommen, G. R. E. V., Verbist, B. M. P., Nijsen, M., Meert, T. F., Wauwe, J. V., & Aerssens, J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.10.091 · Cited by 31
Fischer, B. D., Ward, S. J., Henry, F. E., & Dykstra, L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.005 · Cited by 31
Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor
Dittel, B. N. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707493 · Cited by 31
Effects of neuropeptide FF system on CB1 and CB2 receptors mediated antinociception in mice
Fang, Q., Han, Z., Li, N., Wang, Z., He, N., & Wang, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.09.013 · Cited by 30
Williams, I. J., Edwards, S., Rubo, A., Haller, V. L., Stevens, D. L., & Welch, S. P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.003 · Cited by 29
Szczesniak, A.-M., Maor, Y., Robertson, H. A., Hung, O. R., & Kelly, M. E. M. (2011) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0041 · Cited by 28
Recent advances in the understanding of the role of the endocannabinoid system in liver diseases
Huang, L., Quinn, M. A., Frampton, G. A., Golden, L. E., & DeMorrow, S. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.08.010 · Cited by 23
Paquette, J. J., Wang, H.-Y., Bakshi, K. P., & Olmstead, M. C. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282f15890 · Cited by 22
Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors
Pertwee, R. G., & Thomas, A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-503-9_13 · Cited by 22
Self-citationPertwee, R. G. (2019) · CRC Press eBooks · doi:10.1201/9780429276279-6 · Cited by 22
Self-citationKang, S., Kim, C. H., Lee, H., Kim, D. Y., Han, J. I., Chung, R. K., & Lee, G. Y. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000255291.38637.26 · Cited by 18
Cheng, Y., Pourashraf, M., Luo, X., Srivastava, S. K., Walpole, C. S. J., Salois, D., St-Onge, S., Payza, K., Lessard, E., Yu, X. H., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.124 · Cited by 14
Ruggieri, V., Vitale, G., Filaferro, M., Frigeri, C., Pini, L. A., & Sandrini, M. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.02.006 · Cited by 12
Cited by
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes
Kumari, S., Carmona, A. V., Tiwari, A. K., & Trippier, P. C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00530 · Cited by 654
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
Wen, H., Hockenberry, J. M., & Cummings, J. R. (2015) · Journal of Health Economics · doi:10.1016/j.jhealeco.2015.03.007 · Cited by 379
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.06.016 · Cited by 285
Metadata
- Authors
- Pertwee, R. G.
- Venue
- Philosophical Transactions of the Royal Society B: Biological Sciences
- Publisher
- The Royal Society
- Published
- 2012-12-05
- Volume
- 367
- Issue
- 1607
- Pages
- 3353-3363
- ISSN
- 0962-8436 (ISSN-L)
- 1471-2970
- OpenAlex
- W2113565543
- Cited by
- 347
- References
- 122
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.